Moderna, Inc. (MRNA)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Moderna, Inc. keeps $12 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 12
in 85 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Moderna’s revenue increased year over year in the third fiscal quarter of 2026, with sales up 29.2% to about $1.3 billion (from roughly $1.0 billion a year ago) in results reported November 6, 2026, reflecting continued commercialization of its mRNA vaccine and therapeutics platform across infectious disease and oncology programs. Operating cash flow was negative at about -$1.6 billion, indicating cash usage during the quarter. Consensus for the next period calls for EPS of -$1.73 on revenue of $675.4 million.
About Moderna, Inc.
Moderna, Inc. develops and commercializes messenger RNA medicines and vaccines as a biotechnology company in healthcare, with $1.9 billion in revenue in FY2025. Listed on the NASDAQ Global Select Market under MRNA, the company applies its mRNA platform to preventive vaccines as well as therapeutic programs across infectious disease, oncology, and other treatment categories.
Today's Snapshot
The day ended with MRNA 4.8% lower at 196.79, in line with a weaker sector. Australia’s drug advisers added Moderna’s flu vaccines to a March review agenda.
Trading Volume
Below 10d avg (9.7M)
6.8M
vs S&P 500 Today
Strong Underperformance
-4.58%
Updated: November 18, 2026 at 21:18 UTC
MRNA Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$116.72 - $224.16Sell
- RSI (14)41.45Neutral
- Stochastic %K (14, 3, 3)6.78Buy
- MACD Level (12, 26)3.18Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.